Aura Biosciences, Inc. (AURA)
| Previous close | 7.65 |
| Open | 7.76 |
| Bid | 7.64 x 200 |
| Ask | 7.85 x 200 |
| Day's range | 7.46 - 7.76 |
| 52-week range | 5.99 - 13.50 |
| Volume | |
| Avg. volume | 183,408 |
| Market cap | 374.881M |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.80 |
Simply Wall St.We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
BOSTON, March 27, 2024--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
Insider Monkey11 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]
